Immunocore Holdings (IMCR) Total Liabilities (2019 - 2026)

Immunocore Holdings (IMCR) has reported Total Liabilities for 8 consecutive years, with $678.4 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities rose 4.45% year-over-year to $678.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $678.4 million (up 4.45% YoY) and the FY2025 annual result came in at $686.2 million, up 5.77% from the prior year.
• Total Liabilities slipped to $678.4 million in Q1 2026 per IMCR's latest filing, from $686.2 million in the prior quarter.
• Over the last five years, Total Liabilities for IMCR reached as high as $706.8 million in Q3 2024 and fell as low as $176.6 million in Q3 2022.
• A 5-year average of $527.8 million and a median of $649.5 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities jumped 225.47% — and 2025, when it declined 0.12%.
• Year by year, Total Liabilities stood at $183.9 million in 2022, then grew by 24.09% to $228.2 million in 2023, then jumped by 184.36% to $648.8 million in 2024, then gained by 5.77% to $686.2 million in 2025, then fell by 1.14% to $678.4 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $678.4 million, $686.2 million, and $705.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.